Research programme: gene therapies - Human Genome Sciences/Genentech

Drug Profile

Research programme: gene therapies - Human Genome Sciences/Genentech

Alternative Names: Gene-based therapies - Human Genome Sciences/Genentech

Latest Information Update: 26 Oct 2005

Price : $50

At a glance

  • Originator Genentech; Human Genome Sciences
  • Class
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Immunological disorders; Neurological disorders

Most Recent Events

  • 26 Oct 2005 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 26 Oct 2005 No development reported - Preclinical for Immunological disorders in USA (unspecified route)
  • 26 Oct 2005 No development reported - Preclinical for Neurological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top